CITIUS ONCOLOGY INC (CTOR) Forecast, Price Target & Analyst Ratings

NASDAQ:CTOR • US17331Y1091

Current stock price

0.8152 USD
-0.01 (-1.78%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CITIUS ONCOLOGY INC (CTOR).

Forecast Snapshot

Consensus Price Target

Price Target
$6.12
+ 650.74% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 12, 2026
Period
Q2 / 2026
EPS Estimate
-$0.01
Revenue Estimate
7.137M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.86%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$6.12
Upside
+ 650.74%
From current price of $0.82 to mean target of $6.12, Based on 7 analyst forecasts
Low
$6.06
Median
$6.12
High
$6.30

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

7 Wall Street analysts provided a forecast for the next 12 months for CTOR. The average price target is 6.12 USD. This implies a price increase of 650.74% is expected in the next year compared to the current price of 0.8152.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CTOR Current Analyst RatingCTOR Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

CTOR Historical Analyst RatingsCTOR Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.86%
CTOR was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CTOR.
In the previous month the buy percentage consensus was at a similar level.
CTOR was analyzed by 7 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2025-09-23Maxim GroupUpgrade Hold -> Buy
2025-05-23Maxim GroupDowngrade Buy -> Hold
2024-11-27Maxim GroupInitiate Buy
2024-08-13EF HuttonMaintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 12, 2026
Period
Q2 / 2026
EPS Estimate
-$0.01
Revenue Estimate
7.137M
Revenue Q2Q
N/A
EPS Q2Q
90.73%
Number of Analysts
3

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
-44.00%
EPS (1 Month)
0.00%
EPS (3 Months)
-200.00%

Next Earnings Summary

CTOR is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -0.01 USD and the consensus revenue estimate is 7.14M USD.
The next earnings revenue estimate has been revised downward by 44% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2028

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2022 2023 2024 2025 2026 2027 2028
Revenue
YoY % growth
CTOR revenue by date.CTOR revenue by date.
N/AN/A
205.99%		N/A
32.34%
EBITDA
YoY % growth
CTOR ebitda by date.CTOR ebitda by date.
N/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
CTOR ebit by date.CTOR ebit by date.
-4.857M-12.121M
-149.58%		-20.573M
-69.73%		-23.523M
-14.34%		N/A
88.70%		N/A
2,347.12%		N/A
45.38%
Operating Margin
CTOR operating margin by date.CTOR operating margin by date.
N/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
CTOR eps by date.CTOR eps by date.
N/AN/AN/A-0.34N/A
43.00%		N/A
305.26%		N/A
92.31%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.01
90.73%		0.00
100.00%		-0.11
-87.00%		0.10
270.00%		0.12
1,300.00%		0.000.16
245.45%
Revenue
Q2Q % growth		7.137M11.102M17.387M25.479M
546.68%		29.118M
307.99%		31.545M
184.14%		35.184M
102.36%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-1.278M
82.89%		-167.28K
96.62%		4.143M
187.93%		11.802M
324.70%		14.341M
1,222.09%		15.536M
9,387.42%		18.074M
336.25%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CTOR Yearly Revenue VS EstimatesCTOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 50M 100M 150M
CTOR Yearly EPS VS EstimatesCTOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 0 0.2 -0.2 0.4 -0.4 0.6

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
61.98%
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CITIUS ONCOLOGY INC / CTOR Forecast FAQ

What is the average price target for CITIUS ONCOLOGY INC (CTOR) stock?

7 analysts have analysed CTOR and the average price target is 6.12 USD. This implies a price increase of 650.74% is expected in the next year compared to the current price of 0.8152.

When does CITIUS ONCOLOGY INC (CTOR) report earnings?

CITIUS ONCOLOGY INC (CTOR) will report earnings on 2026-05-12.

Can you provide the consensus estimates for CITIUS ONCOLOGY INC next earnings?

The consensus EPS estimate for the next earnings of CITIUS ONCOLOGY INC (CTOR) is -0.01 USD and the consensus revenue estimate is 7.14M USD.

Can you provide the consensus rating for CITIUS ONCOLOGY INC stock?

The consensus rating for CITIUS ONCOLOGY INC (CTOR) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.